GlycArt
Roche’s MabThera successor shows phase II promise
December 6, 2010Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia
The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …
GlycArt’s new cancer candidate to be developed with Roche
October 9, 2008Research and Development, Sales and Marketing GlycArt, Roche
Roche is to develop a potential cancer therapy with two business partners. Genentech, the Swiss biotech company GlycArt – wholly-owned …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
